Related Experiment Video
Updated: Feb 12, 2026

Area-based Image Analysis Algorithm for Quantification of Macrophage-fibroblast Cocultures
Published on: February 15, 2022
Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
Basim Mohammad Ayesh1,1, Ahmed Shaker Abu Shaaban2,2, Abdalla Asaf Abed3,3
1Department of Laboratory Medical Sciences, Faculty of Applied Sciences, Alaqsa University, Gaza, Palestine.
Insights
The international warfarin pharmacogenetics consortium algorithm accurately predicts stable warfarin dose in Palestinian patients. This pharmacogenetic approach offers a reliable method for personalized warfarin dosing in this population.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Genomics
Background:
- Warfarin dosing requires careful management due to its narrow therapeutic index.
- Genetic variations in CYP2C9 and VKORC1 significantly influence warfarin metabolism and response.
- Predictive algorithms aim to optimize warfarin dosage for individual patients.
Purpose of the Study:
- To assess the applicability of a warfarin pharmacogenetics algorithm for predicting stable warfarin dose (WSD) in Palestinian patients.
- To compare the performance of the international warfarin pharmacogenetics consortium algorithm against clinical and fixed-dose algorithms.
Main Methods:
- Retrospective calculation of warfarin doses for 101 Palestinian patients using three distinct models.
- Evaluation of algorithm performance in a subset of 47 patients who had achieved a stable warfarin dose.
- Analysis included CYP2C9*2, *3, and VKORC1-1639G>A allele frequencies.
Main Results:
- The frequency of CYP2C9*2, *3, and VKORC1-1639G>A alleles in the study population was 13.6%, 0.0%, and 46.5%, respectively.
- The international warfarin pharmacogenetics consortium algorithm demonstrated superior reliability with a Mean Absolute Error (MAE) of 8.9 ± 1.4 and R² of 0.350.
- Both the clinical algorithm (MAE = 10.4 ± 1.4; R² = 0.128) and the fixed-dose algorithm (MAE = 11.1 ± 1.7) showed lower reliability.
Conclusions:
- The international warfarin pharmacogenetics consortium algorithm is a reliable tool for predicting stable warfarin dose in the Palestinian population.
- Pharmacogenetic-guided dosing can improve warfarin therapy management in this demographic.
- Further validation in larger cohorts is recommended to solidify these findings.
Aim:
To evaluate applicability of CYP2C9*2, *3 and VKORC1-1639G > A based algorithm to predict warfarin stable dose (WSD) in a group of Palestinian patients.
Patients & Methods:
Warfarin doses were retrospectively calculated for 101 Palestinian patients under warfarin therapy using three models. Performance of the three models was assessed in 47 patients found to take WSD.
Results:
Frequency of CYP2C9*2, *3 and VKORC1-1639G > A alleles is 13.6, 0.0 and 46.5% respectively. The international warfarin pharmacogenetics consortium algorithm was more reliable (MAE = 8.9 ± 1.4; R2 = 0.350) than both the clinical algorithm (MAE = 10.4 ± 1.4; R2 = 0.128;) and the fixed-dose algorithm (MAE = 11.1 ± 1.7).
Conclusion:
The international warfarin pharmacogenetics consortium algorithm can be reliably applied for predicting the WSD in Palestinian population.
More Related Videos
09:52Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
Published on: January 15, 2017
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Metabolism: Overview
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Principles of Pharmacogenetics: Types of Genetic Variants
Trial and Error and Algorithm
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes